Aethlon Medical to merge with North Immunology; AEMD holders keep ~4.75% of ~$346.5M combined company

Aethlon Medical and private North Immunology announced an all-stock merger to advance an IL-13 x IL-18 bispecific antibody for atopic dermatitis. Aethlon holders retain ~4.75% of the combined company, valued at ~$346.5M pro forma, with an oversubscribed $180M PIPE; ticker becomes NRTX.

Detected & updated continuously · Source: Nebula